Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute
News Feb 02, 2015
Horizon Discovery Group plc has been selected to act as a core facility by the Tri-Institutional Therapeutics Discovery Institute (TDI). As a core facility, Horizon will provide single and combination drug profiling followed by confirmatory secondary assay services to TDI through its discovery research services unit.
Under the agreement, Horizon will receive up to $500,000 for work to be performed during 2015 and 2016, with the option for additional collaboration work orders thereafter.
Horizon will utilize its unique cHTS (combination High Throughput Screening) platform and Chalice™ analytics software to screen and analyze potentially thousands of small-molecule drugs, therapeutic antibodies or proteins in combination to identify synergistic or antagonistic interactions. Horizon will also provide a range of optimized cellular assays as follow-ups to identify drug target activity. The first programs are forecast to start in the second half of 2015.
Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “Horizon is thrilled to have been chosen as a core facility to support TDI research programs via application of our innovative drug combination screening platform and assay services. The partnership, which provides access to multiple components of our technology platforms and capabilities, reinforces the value that we can provide our customers from ‘sequence to treatment’. We look forward to working with the TDI team and potentially broadening our relationship further in 2016 and 2017.”
Dr. Michael Foley, Sanders Director, TDI, said: “The Tri-Institutional Therapeutics Discovery Institute links researchers in basic and clinical science with experts in drug discovery from the biotech and pharmaceutical industries, with the goal of more efficiently translating discoveries into therapies for disease. We are delighted to be partnering with Horizon Discovery Group and look forward to initiating the programs.”
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Antimicrobial Found in Toiletries Could be Used Against MalariaNews
Triclosan, an antimicrobial compound used in soap, toothpaste, deodorant and many other products, can inhibit target genes in the malaria parasite during two crucial stages of its lifecycle in humans - the hepatic stage.READ MORE
Pre-Treatment with Targeted Drugs Could Mean Less Breast Cancer Patients Require Radical SurgeryNews
Extensive surgery involving mastectomy and removal of several lymph nodes can be safely avoided for more women with some types of breast cancer, if they receive targeted drugs before surgery, according to research presented at the 11th European Breast Cancer Conference.READ MORE